Delivery Order SPE2DB20D2104-SPE2DB24FMASB

Award Date 9/3/24
Potential Completion Date 9/4/24
Potential Value $6.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,464.59 firm fixed-price delivery order is for the supply of XHANCE 93 MCG NASAL SPRAY 16ML, a prescription medication. The contract has an ultimate completion date of May 9, 2025 and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,624.40 firm fixed-price delivery order is for the supply of XHANCE 93 MCG Nasal Spray 16ML, a pharmaceutical product. The contract has an ultimate completion date of December 11, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of XHANCE 93 MCG Nasal Spray 16ML. The $4,796.97 firm-fixed-price delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for providing a wide range of medical commodities to support military treatment programs...
This federal contract award, valued at $4,633.32, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of XHANCE 93 MCG NASAL SPRAY 16ML. The contract has an ultimate completion date of April 14, 2025 and is a Firm Fixed Price Delivery Order. The contract is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a...
This federal contract award, with an identifier of SPE2DB20D2104 and SPE2DB24FMCKH, is a delivery order between the Defense Logistics Agency (DLA) and AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,643.86, is for the supply of XHANCE 93 MCG NASAL SPRAY 16ML, a pharmaceutical product. The contract has a firm fixed price pricing type and an ultimate completion date of September 30, 2024. AmerisourceBergen Drug Corp, a...
This federal contract award, with ID SPE2DB22D3004|SPE2DB25FQJ66, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of XHANCE 93 MCG NASAL SPRAY 16ML, a prescription medication. The contract has a ceiling value of $2,572.88 and is a Firm Fixed Price Delivery Order, with an ultimate completion date of April 23, 2025. The contract is not set aside and was awarded on...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of XHANCE 93 MCG NASAL SPRAY 16ML. The $4,281.82 firm fixed-price delivery order has a completion date of December 10, 2024 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award, identified as SPE2DB20D1004|SPE2DB25FNDQP, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XHANCE 93 MCG NASAL SPRAY 16ML, a prescription medication. The fixed-price contract has a ceiling value of $1,183.44 and an ultimate completion date of December 20, 2024. The award does not have a set-aside designation, indicating open...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp's Corporate Office Division for the delivery of the pharmaceutical product XHANCE 93 MCG NASAL SPRAY 16ML. The contract has a firm fixed price of $1,300.96 and a completion date of June 26, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, valued up to $999,999,999.00 through December 31, 2025, which serves...
This federal contract award, identified as SPE2DB22D6029|SPE2DB24FU1QV, is a delivery order from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of XHANCE 93 MCG Nasal Spray 16ML. The contract has a ceiling value of $1,143.90 and is a firm fixed-price type, with a performance period ending on July 18, 2024. This award is not set aside for any specific business category. AmerisourceBergen, through its Corporate Office Division,...
  • SPE2DB20D2104
    Indefinite Delivery Contract
  • SPE2DB20D2104-SPE2DB24FMASB
    Delivery Order

This federal contract award, with ID SPE2DB20D2104|SPE2DB24FMASB, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $6,313.67 Firm Fixed Price contract is for the delivery of XHANCE 93 MCG Nasal Spray 16ML, with a completion date of September 4, 2024. The contract is not designated as a set-aside.

AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation through May 2024, covering similar medical products and prescription drugs.

Generated 2/27/25, 10:44 AM